Therapeutic Response

MSI-H status confers therapeutic sensitivity to Ipilimumab in combination with Nivolumab in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Opdivo (nivolumab) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Yervoy (ipilimumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.